

The concentration and type of monoclonal protein and their impact on clinical severity in patients with symptomatic myeloma

Najmaddin Salih Husen Khsohnaw¹, Ahmed Khudair Yassin², Sana Dlawar Jalal³, Akram Mahmood Mohammed¹, Kawa Mohamedamin Hasan², Dana Ahmed Abdulla³, Ameer Badi⁴, Banaz Mubarak Safar¹, Basil Kadhim Abdulla¹, Rawand Polus Shamoon⁷, Diveen Jalal Hussein⁵, Nawsherwan Sadiq Mohammed⁷, Kanar Jalal Karim¹, Abid Mohiaddin Hassan⁶, Hisham Arf Getta³, Rezhin Nawzad Rajab⁵, Friad Hiwaizi⁵, Truska Awat Amin¹, Zeki Ali Mohamed⁶, Ali Ibrahim Mohammed³, Hameed Saeed¹, Parween Ismael¹, Alaa Alwan⁸

Abstract

Background and objectives: Multiple Myeloma is a clonal plasma cell proliferation in the bone marrow that produces abnormal monoclonal proteins in serum and /or urine that leads to end-organ damage. We aimed to evaluate concentration, type of monoclonal protein, and their impact on the severity of symptomatic multiple myeloma patients. **Methods:** The study was conducted on 124 patients with symptomatic myeloma who were registered in the three centers in Kurdistan-Iraq from January–June 2019. Out of the 74 were males, and 50 were females. Demographic details, laboratory investigations, imaging study were reviewed, and informed consent was obtained for all patients; smoldering myeloma was excluded. **Results:** The most prevalent subtypes were IgG followed by IgA (61.3%, 18.5% respectively), whereas free light chain and non-secretory myeloma forming the rest, 12.1% and 6.45% for each subtype. There is a statistically positive association found between the concentration of monoclonal protein and the level of hemoglobin, β_2 -microglobulin, and lactic acid dehydrogenase. There is no association for the concentration of monoclonal protein with each of calcium, albumin, creatinine, and erythrocytes domination rate. **Conclusions:** We found a higher percentage of IgG/Kappa, high rates of non-secretory myeloma, low rates of light chain myeloma and younger age at presentation in comparison to western reports. The association between monoclonal protein concentration and some parameter of prognostic value in patients studied underscores its relevance to severity of disease in our locality.

Keywords: Multiple Myelomas; Immune-fixation; Light chain; Serum and Urine Protein electrophoresis.

The concentration and type of monoclonal protein and their impact on clinical severity in patients with symptomatic myeloma

*** Corresponding author:** Dr. Najmaddin Salih Husen Khoshnaw, E-mail: najmaddin.salih@gmail.com

¹ MBChB, HDH, KBMS-candidate Department of Haematology, Hiwa Cancer hospital, Sulaymaniyah, Ministry of Health, Department of MLS, Komar University of Science and Technology, Kurdistan region, Iraq.

² MBChB, CABM, FIBMS, Department of Medicine, College of Medicine, Hawler Medical University, Kurdistan Region, Iraq.

³ Department of Pathology, College of Medicine, University of Sulaimani, Kurdistan Region, Iraq.

⁴ Department of Pathology, College of Medicine, University of Duhok, Duhok, Kurdistan Region, Iraq.

⁵ Department of Haematology, Nanakali Hospital, Erbil, Kurdistan Region, Iraq.

⁶ Department of Medicine, College of Medicine, University of Duhok, Duhok, Iraq.

⁷ Department of Pathology, College of Medicine, Hawler Medical University, Erbil, Iraq.

⁸ Department of the Haematology University of Mustansiriyah, National Center of Hematology, Baghdad, Iraq.

Introduction

Multiple myelomas (MM) are a type of malignancy that arises from clonal plasma cells overgrowth in bone marrow with the production of an abnormal monoclonal (M)-protein in the serum and/or urine¹. Myeloma may be asymptomatic, smoldering (no-end-organ-damage), and symptomatic myeloma when there is end-organ damage. The end-organ damage includes hypercalcemia, renal dysfunction, anemia, and bone lesion abbreviated as (CRAB)². Symptomatic MM can be diagnosed by the presence of 10% or more clonal plasma cells in bone marrow trephine biopsy or biopsy-proven bony or extramedullary plasmacytoma plus any one or more of the CRAB features and myeloma-defining events. Depending on the revised International Myeloma Working Group (IMWG), the myeloma defining events includes either 60% or higher clonal plasma cells on marrow trephine biopsy,

serum involved to uninvolved free light chain ratio of 100 and one or more lytic lesion greater than five mm on resonant magnetic imaging (MRI)³. Serum and urine protein electrophoresis (SPE, UPE) with immune fixation (IF) have been used for screening, staging, and monitoring of plasma cell disorders⁴. Despite less sensitivity, SPE and UPE are the most commonly used laboratory test for screening plasma cell disorder⁵. The free light chain assay (FLC) and the ratio will give additional sensitivity for diagnostic screening in patients with clinical features of MM, reaching 99%⁶. About 5% of symptomatic MM is non-secretory in case of using SPE and UPE for screening, but nearly about two-third of them could have free clonal immunoglobulin light chains in blood by doing FLC assay⁷. Malignant plasma cells most commonly produce an IgG (50%), IgA

(20%), or light chain only (20%) monoclonal protein⁸. Prognosis depends on age, performance status, and serum albumin, stage of the disease, beta 2-microglobulin (β 2M), cytogenetic, lactic acid dehydrogenase (LDH), C - reactive protein (CRP), plasma cell labeling index, IL6, and bone marrow microenvironment. The

Patients and methods

The study was conducted on 124 patients with symptomatic myeloma who were registered in the three centers in Kurdistan-Iraq {Hiwa (sulaimani), Nanakali (Erbil), and Azadi (Duhok)} from January–June 2019, of them: 74 were males, and 50 were females. Demographic details, laboratory investigation concentrating on SPE, UPE, IF, biochemistry, calcium, serum albumin, and bone marrow aspirate/trephine biopsy, flow cytometry, and skeletal bone imaging. Written informed consent was obtained from all patients; smoldering myeloma was excluded. The revised International myeloma working group (IMWG) criteria were applied for the diagnosis of all patients³. Evidence of end-organ damage was defined as hypercalcemia: serum calcium

Results:

Out of 124 patients with newly diagnosed symptomatic MM, 74 (59.7%) males, and 50

international prognostic index used as a prognostic tool for symptomatic myeloma patients⁹. The study aimed to detect the concentration and types of abnormal M-protein in blood and urine. The second aim is to correlate the amount and kind of M-protein versus disease severity at presentation.

$\geq 1\text{mg/dL}$ higher than the upper limit of normal or ($\geq 11\text{mg/dL}$), renal insufficiency: creatinine clearance $\leq 40\text{ mL /minute}$ or serum creatinine $\geq 2\text{mg/dL}$, anemia: hemoglobin of $\leq 10\text{g/dl}^3$. We used Graft Pad Prism version 5.0 for statistical analysis. The age of the patients measured as a mean age $\pm\text{SD}$. The relationship between two continuous data was measured by coefficient correlation (Pearson test) and ANOVA with the post-Tukey test used for detecting statistical significance among means of different categories. Mann Whitney U test was used for testing the significant difference of median among different groups (p-value below 0.05 considered statistically significant).

(40.3%) females, males to female's ratio of 1.48:1. The median age was 61 years with a

The concentration and type of monoclonal protein and their impact on clinical severity in patients with symptomatic myeloma

range between 35-89 years, about 2.4% of the age and sex distribution of the enrollees. them were below 40 years. Table (1) shows

Table (1): The Demographic characteristics, including age and sex distribution of 124 patients with symptomatic myeloma at the presentation of the disease.

Factor		No. (%)
Age	<40	3(2.4)
	40-49	18(24.5)
	50-59	34(27.4)
	60-69	39(31.5)
	70-79	21(16.9)
	≥ 80	9 (7.25)
	Median	61
	Range	35-89
Sex	Male	74(59.7)
	Female	50(40.3)

The IF and SPE pattern showed a localized band or spike in nearly 80.6 % of cases, with hypo-gammaglobulinemia in the rest. In those patients with positive M-band in serum, the most frequent M-protein subtype was IgG, which accounts for about 66 (61.3%), followed by IgA in 18.5% of patients and the free light chain myeloma

(LC M) accounts for only 15(12.1%); Non-Secretory Myeloma (NSM) was documented in 6.45%, and lastly bi-clonal (IgG and IgA) 1 (0.8%) and IgD 1(0.8%). Among those with the positive band in the serum, the kappa was 70%, while lambda 30% of patients (Table 2).

Table (2): The distribution of types and percentage of monoclonal protein among the patients with symptomatic myeloma.

Types	No. (%)
IgG κ	57(45.9)
IgG λ	19(15.3)
IgA κ	10(8)

The concentration and type of monoclonal protein and their impact on clinical severity in patients with symptomatic myeloma

IgA λ	13(10.5)
Biclonal	1(0.8)
IgD κ	1(0.8)
IgD λ	0(00)
Free κ only	9(7.25)
Free λ only	6(4.8)
No band	8(6.45)
Total	124(100)

A monoclonal light chain protein in the urine (BJP) found in 77 (62%) of patients. In patients who had M-protein in serum, urine BJP was detected in nearly 93.55% of patients. The median concentration of serum M-protein in our study was 3 gm/dl ranging from (0.3-6) and median urine BJP concentration of 42 mg/dl ranging from 2-

970 mg/dl. (Table 3). The Calcium level was elevated above the >11 mg/dl in 17 (13.3 %) of patients at diagnosis. Renal involvement with serum creatinine above 2 mg/dl, found in 31 (25.6%) and bone pain, was found in 98 (79 %) of patients while bone lesions detected in nearly 75 (59.7%).

Table (3): Laboratory blood test results among the 124 patients with symptomatic myeloma at presentation.

Blood tests	No. of patients	Median	Range	Distribution of results	% of patients
Hb (gm/dl)	121	10.1	6-16	≤ 10	16.12
				8.1-10	33.87
				10.1-12	31.45
				>12	18.54
Serum M-Protein Concentration (gm/dl)	100	3	0.3-6	≤ 0.9	7
				1.0-1.9	5
				2.0-2.9	35
				3.0-3.9	18
				4.0-4.9	26
				>5	9
Urine M-protein	72	42	2-970	<15	23.6

The concentration and type of monoclonal protein and their impact on clinical severity in patients with symptomatic myeloma

Concentration (mg/dl)				16-100	50
				≥ 100	26.4
Serum creatinine mg/dl	124	1.1	0.1--10.6	≤ 1.2	58.3
				1.3-1.9	19.1
				≥ 2	25.6
Serum Calcium mg/dl	124	9.2	7.8-15	≤ 10	74
				10.1-10.9	12.67
				≥ 11	13.33
B2M (mg/L)	80	4.1	0.4-17	< 3.5	40
				3.5-5.5	25
				> 5.5	33.75
LDH (U/L) Reference(140-280)	113	310	18-812	< 280	44.24
				> 280	53.76

The number of osteolytic bone lesions per site was 144/101 (sites/patients) in those with positive serum M-band (1.4 bone lesion /patient). In the case of LCM and NSM, we found a statistically non-significant (p-value 0.28) higher number of the osteolytic bone

lesion in comparison to those with only positive serum M-protein, 2.13/1, and 2/1; respectively. The most frequent sites were spine, skull, pelvis, humerus, and femurs (Table 4).

Table(4): Number and site of osteolytic bone lesions in those patients with positive serum M-protein, LCM, and NSM.



Site of osteolytic bone lesions	Myeloma with a serum M- band	Type of myeloma	
		LCM	NSM
lumber sacral	62	9	6
skull	34	2	4
pelvis and sacrum	12	4	3
dorsal spine	10	5	2
Humerus	9	1	0
femur,	7	3	0
plasma cytoma	2	2	0
ribs	6	1	1

The concentration and type of monoclonal protein and their impact on clinical severity in patients with symptomatic myeloma

radius	1	4	0
cervical Spine	1	1	0
total bone lesions	144	32	16
Number of patients	101	15	8

When patients were categorized into groups according to their hemoglobin, it was found that those with higher M-band concentration were associated with lower hemoglobin categories. ($P=0.0309$). (Fig.1A). We detected serum $\beta 2M > 5.5$ mg/L in 33.75% of patients, which indicates stage three of the disease according to the international staging system (Table 3). Furthermore, we found a positive relationship between the

concentration of serum M-protein and serum $\beta 2M$. The higher the amount of M-protein in the serum, the higher the $\beta 2M$. (Fig 1B). The LDH (>280 U/L, reference range (140-280 unit/L) was raised in more than 53 % of our patients at presentation. We found a positive association between serum M-protein and LDH but it was statistically non-significance (p-value 0.796). (Fig.1C).







Figure (1): Comparing the amount of serum M-protein concentration with each of Hb (A), and B2M (B) and LDH (C).

We could not find a statistically significant association between the concentration of serum protein in gm/dl with each of the performance status (ECOG) (Fig.2), calcium, albumin, creatinine, and erythrocyte sedimentation rate ESR (p-values were 0.51, 0.1154, 0.287, 0.78 respectively). There was no relation between the median of each of albumin, calcium,

creatinine, Hb, and ESR with the type of symptomatic MM (positive M-band, LCM and NSM). The median percentage of plasma cells in marrow aspirate was 40%, not related to the amount of serum M-protein and no difference found in the proportion in those with positive serum M-protein, LCM, or NSM patients using Mann Whitney U test.



Figure(2): The serum M-protein concentration versus ECOG performance status

Discussion

The median age at diagnosis in our study was 61 years, while in a study done by Kyle et al., it was 66 years¹³. The earlier age presentation is valid for all types of cancer in our region, as reported previously¹⁰⁻¹². We used SPE and UPE with IF but not using the FLC assay; for that reason, we found a higher percentage of NSM (6.45%) in our study, while other studies report only 3%¹³ and 5%¹⁰. nearly about two-third of those who have NSM have a positive light chain by using FLC assay according to previously reported studies^{5-7, 14,15}. We found M-protein in almost 80.6%, which is near to that found by Kyle et al., who reported it in 82% of his cases¹³. The most prevalent M-protein subtype was IgG, which accounts for about 61.3% and IgA in 18.5%, while the lower percentage recorded (IgG in 50% and IgA in 20%) by RajKumar⁸ & Kyle⁸. The free LCM accounts for only 12.1% (kappa 7.25% and lambda 4.85%), which is lower than that reported by earlier studies, which was 20%^{4, 13}. It has been reported among those with the positive M-band in the serum the kappa was found in 63%, while lambda is 37%¹³, which is similar to our study 70% kappa (κ) and 30 % lambda (λ). A monoclonal light chain found in 62% of

cases, which related to more renal impairment at the time of diagnosis, as we saw in nearly 25% of our patients¹⁶. Anemia (Hb less or equal to 12 gm/dl) found in 81.4% of patients, which similar to that report by Rajkumar & Kyle⁸. Renal impairment with creatinine > 2mg/dl found in about 18.5 % of cases in our study at diagnosis, while a higher figure (40%) was reported in an earlier study¹⁶. Hypercalcemia in our research found in 13.33%, which similar to that reported by Kyle et al. 13%¹³. Bone pain was found in 98(79 %) of patients, while bone lesions detected in nearly 75 (59.7%) while less bone pain and less bone lytic lesion found in a study published by Palumbo et al. and Yassin^{10,17}. We found higher osteolytic lesion sites per each person in both LCM (2.13/1) and NSM (2/1) in comparison to those with positive serum M-band MM 1.4/1 cases, but have no statistical significance, as shown in (Table4). We found a positive relationship between the amount of serum M-protein and serum β 2M (Fig.1B) but in other studies, showed no prognostic significance, although β 2M is an essential value in the staging of the symptomatic myeloma in international staging system^{16, 18}. In our study, more than

53% of patients recorded to have a high level of LDH. The LDH concomitantly elevated with the serum M-protein as shown in (Fig.1C). As we know, LDH associated with defining prognosis as put in a newly revised international staging system (ISS-R)¹⁹⁻²¹. Besides the use of concentration and type of M-protein in urine and serum for the diagnosis of plasma cell disorders (MGUS, smoldering myeloma, and symptomatic myeloma), it may be used to detect clinical

Conclusions

In our study, we found a higher percentage of IgG/Kappa in serum, high rates of NSM, low rates of LCM, and younger age at presentation of symptomatic myeloma in comparison to other studies reported in the literature.

Conflict of interests

The authors recorded no conflict of interests.

References

1. Kyle RA, Larson DR, Therneau TM, et al. Long-term follow-up of monoclonal gammopathy of undetermined significance. *N Engl J Med*. 2018;378(3):241–9.
2. Rajkumar SV. Updated Diagnostic Criteria and Staging System for Multiple Myeloma. *Am Soc Clin Oncol Educ B*. 2016;36: e418–23.

severity of myeloma at presentation as we found some positive relation with Hb level and $\beta 2M$ (Fig.1A,B) . On the other hand, we could not find a positive association with some other values, as explained in results.

Despite the limitation in using serum-free light chain assay and cytogenetic tests in our study, but still, the SPE, UPE, and IF give us a definite clue in assessing the severity of the disease at diagnosis.

The SPE, UPE and IF still can be in use in assessing severity of disease in our locality because they have been found to be associated with some well documented prognostic factors.

3. Rajkumar SV, Dimopoulos MA, Palumbo A, et.al. International Myeloma Working Group (IMWG) criteria for the diagnosis of multiple myeloma. *Lancet Onco*. 2014;15(12):538–48.
4. O’Connell TX, Horita TJ, Kasravi B. Understanding and interpreting serum protein electrophoresis. *Am Fam Physician*. 2005;71(1):105–12.

5. Dispenzieri A, Kyle R, Merlini G, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. *Leukemia*. 2009; 23:215–24.
6. Greipp P, San Miguel J, Brian G et.al. International Staging System for Multiple Myeloma. *J Clin Oncol*. 2005 23:15, 3412-20.
7. Drayson M, Tang LX, Drew R, et.al. Brief report Serum free light-chain measurements for identifying and monitoring patients with non-secretory multiple myeloma. *Blood*. 2001;97(9):2900–2.
8. Rajkumar SV, Kyle RA. Multiple myelomas: diagnosis and treatment. *Mayo Clin Proc*. 2005;80(1): 80:1371-82.
9. Munshi NC. Investigative tools for diagnosis and management. *Hematology Am Soc Hematol Educ Program*. 2008:298-305.
10. Yassin AK. Clinical and Laboratory Profiles of 109 Patients diagnosed as Multiple Myeloma in Erbil City. *J Fac Med Baghdad*. 2013;55(2):121–4.
11. Khoshnaw N, Mohammed HA, Abdullah DA. Patterns of Cancer in Kurdistan - Results of Eight Years Cancer Registration in Sulaymaniyah Province-Kurdistan-Iraq. *Asian Pac J Cancer Prev*. 2015;16(18):8525-31.
12. Yassin AK. Survival advantage of adding thalidomide as compared with chemotherapy only in the treatment of symptomatic myeloma in Kurdistan/Iraq. *Iraqi J Hematol*. 2016;42(1):9–14.
13. Kyle RA, Gertz MA, Witzig TE et al. Review of 1027 patients with newly diagnosed multiple myeloma. *Mayo Clin Proc*. 2003;78(1):21-33
14. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. *Leukemia*. 2006; 20:1467–73.
15. Katzmann JA, Dispenzieri A, Kyle RA, et.al. Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays. *Mayo Clin Proc*. 2006; 81:1575–8.
16. Eleutherakis-Papaiakevou V, Bamias A GD. Renal failure in mul-tiple myeloma: incidence, correlations, and prognostic significance. *Leuk Lymphoma*. 2007; 48:48:337-41.
17. Palumbo A, Anderson K. Multiple Myeloma. *N Engl J Med*. 201; 364:1046–60.
18. Durie BG. The role of anatomic and functional staging in myeloma: description

of Durie/Salmon plus staging system. Eur J Cancer. 2006;42(11):1539-43.

19. Hari PN, Zhang MJ, Roy V, et al., Is the international staging system superior to the Durie – Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant. Leukemia. 2009;23(8):1528–34.

20. Avet-Loiseau H, Attal M, Moreau Ph., et.al. Genetic abnormalities and survival in

multiple myeloma: the experience of the Intergroupe Francophone du Mye' lome. Blood. 2007;109(8):3489–95.

21. Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised International Staging System for Multiple Myeloma: A Report from International Myeloma Working Group. J Clin Oncol.2015; 33:26, 2863-9.